LG Life Sciences and Mochida signed the contract for Humira biosimilar

October 20, 2014 7:03 AM

LG Life Sciences Ltd. and Mochida, Japan signed agreement for Humira biosimilar, treatment for the autoimmune disease, in Japan market.

Mochida will have exclusive right for developing and sales of Humira biosimilar in Japan which is currently in clinical study by LG Life Sciences. After commercialization, LG Life Sciences will supply drug product to Mochida.

LG Life Sciences said, The agreement for Humira biosimilar was signed with Mochida following the agreement of Enbrel” and explained that the initial development fee for own biosimilar technology and milestone payment for each step will be given to us accelerate distribution
for both Korea and Japan market”

The company also said that “We plan to penetrate into developing countries by various type of partnership”.

Mochida was founded in 1913 as one of the Japan’s pharmaceutical and healthcare companies. The company specializes in product development and commercialization with experiences through biosimilar approval process.

As LG Life Sciences are supported by Regional Industry Supporting Project of South Korean government for developing Humira biosimilar in 2011 and this license agreement is evaluated as successful project supported by government.

Source: LG Life Sciences press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!